PA Request Criteria

CAREFIRST - MD EXCHANGE 5T Omega-3 Fatty Acids (HMF)

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 888-836-0730. Please contact CVS/Caremark at 855-582-2022 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Omega-3 Fatty Acids (HMF).

Patient Information			
Patient Name:			
Patient Phone			
Patient ID:			
Patient Group No:			
Patient DOB: / / / / / / / / / / / / / / / / / / /			
Prescribing Physician			
Physician Name:			
Physician Phone:			
Physician Fax			
Physician Address:			
City, State, Zip:			
Drug Name (select from list of drugs shown) Omega-3-Acid CAP 1 GM			
Officga 5 Act	TON TOW		
Quantity:	Frequency: Strength:		
Quantity: Route of Admi	Frequency: Strength: nistration: Expected Length of Therapy:		
-	-		
Route of Admi	nistration: Expected Length of Therapy:		
Route of Admi	nistration: Expected Length of Therapy:		
Route of Admi Diagnosis: Comments: Please check 1. Does the triglyceric	nistration: Expected Length of Therapy:	Υ 🗆	N 🗆
Route of Admi Diagnosis:	he appropriate answer for each applicable question. patient have, or did the patient have prior to the start of treatment with a e lowering drug, a triglyceride level greater than or equal to 500		N
Route of Admi Diagnosis: Comments: Please check of the triglyceric milligrams 2. Is this recommendation of the triglyceric milligrams 3. Is Vascep revascular	he appropriate answer for each applicable question. patient have, or did the patient have prior to the start of treatment with a e lowering drug, a triglyceride level greater than or equal to 500 s/deciliter?	Y 🗆	_
Route of Admi Diagnosis:	he appropriate answer for each applicable question. patient have, or did the patient have prior to the start of treatment with a e lowering drug, a triglyceride level greater than or equal to 500 s/deciliter? uest for Vascepa? a being prescribed to reduce the risk of myocardial infarction, stroke, coronary rization, or unstable angina requiring hospitalization in an adult patient with	Y 🗆	N 🗆
Route of Admit Diagnosis:	he appropriate answer for each applicable question. patient have, or did the patient have prior to the start of treatment with a e lowering drug, a triglyceride level greater than or equal to 500 s/deciliter? uest for Vascepa? a being prescribed to reduce the risk of myocardial infarction, stroke, coronary rization, or unstable angina requiring hospitalization in an adult patient with riglyceride (TG) levels (greater than 150 milligrams/deciliter)?	Y	N
Route of Admit Diagnosis:	he appropriate answer for each applicable question. patient have, or did the patient have prior to the start of treatment with a e lowering drug, a triglyceride level greater than or equal to 500 s/deciliter? uest for Vascepa? a being prescribed to reduce the risk of myocardial infarction, stroke, coronary rization, or unstable angina requiring hospitalization in an adult patient with riglyceride (TG) levels (greater than 150 milligrams/deciliter)? patient have established cardiovascular disease?	Y	N

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Г

Effective July 1, 2015, Maryland law will require providers to submit pharmaceutical preauthorization requests electronically. To use ePA, either contact your electronic health record vendor or visit www.covermymeds.com/epa/caremark